Follow our progress

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that…

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 – 10:00 AM ET.

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH,…

PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a…

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE…

LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as…

NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet…

LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that senior…

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that…